Characterization and clinical evaluation of CD10 + stroma cells in the breast cancer microenvironment

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1004-1014

  Desmedt, Christine ^a   Majjaj, Samira ^a   Kheddoumi, Naima ^a   Singhal, Sandeep K ^a   Haibe Kains, Benjamin ^a,c   El Ouriaghli, Frank ^a   Chaboteaux, Carole ^a   Michiels, Stefan ^a   Lallemand, Françoise ^a   Journe, Fabrice ^a   Duvillier, Hughes ^a   Loi, Sherene ^a   Quackenbush, John ^c   Dekoninck, Sophie ^b   Blanpain, Cédric ^b   Lagneaux, Laurence ^a   Houhou, Nawal ^d   Delorenzi, Mauro ^d   Larsimont, Denis ^a   Piccart, Martine ^a   Sotiriou, Christos ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b Interdisciplinary Research Institute (IRIBHM)   (Belgium)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; STROMELYSIN 3; TRANSCRIPTION FACTOR RUNX2;

ADH1B GENE; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CD10+ STROMA CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL POPULATION; CLINICAL ARTICLE; COL10A1 GENE; CONTROLLED STUDY; FIBROBLAST; GENE; GENE EXPRESSION PROFILING; GJB2 GENE; GPX3 GENE; GRP GENE; HSD17B6 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MATN3 GENE; MESENCHYMAL STEM CELL; MMP11 GENE; MMP13 GENE; MYOEPITHELIUM CELL; OSTEOBLAST; PCOLCE2 GENE; POSTN GENE; PPAPDC1A GENE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; STROMA CELL; TUMOR MICROENVIRONMENT;

BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM STAGING; NEPRILYSIN; PROGNOSIS; ROC CURVE; STROMAL CELLS; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84857096700     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0383     Document Type: Article

References (35)

1. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32. (Pubitemid 38903159)
2. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009;11:R7.
3. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat 2009;114:47-62.
4. Bauer M, Su G, Casper C, He R, Rehrauer W, Friedl A. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 2010;29:1732-40.
5. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27. (Pubitemid 351655218)
6. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14:5158-65.
7. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009;15:68-74. Erratum in: Nat Med 2009;15:220.
8. Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 2006;8:R58.
9. Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, et al. Human marrow mesenchymal stem cell culture: serum-free medium allows better expansion than classical alpha-MEM medium. Eur J Haematol 2006;76:309-16. (Pubitemid 43362939)
10. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;20:307-15. (Pubitemid 38262761)
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;B:289-300.
12. Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, Lu TH, et al. GeneSigDB - a curated database of gene expression signatures. Nucleic Acids Res 2010;38(Database issue):D716-25.
13. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
14. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006;66:5278-86. (Pubitemid 43844952)
15. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, et al. MAQC Consortium. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006;24:1151-61. (Pubitemid 44359727)
16. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14. (Pubitemid 46944903)
17. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365: 671-9. (Pubitemid 40260888)
18. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 2007;104:6740-5. (Pubitemid 47175571)
19. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5. Erratum in: Proc Natl Acad Sci U S A 2005;102:17882. (Pubitemid 41420886)
20. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72. (Pubitemid 43264710)
21. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune systemhas a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-13.
22. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
23. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. Agene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
24. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
25. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van't Veer L, et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 2008;9:394.
26. Cochrane WG. Problems arising in the analysis of a series of similar experiments. J R Stat Soc 1937;4:102-18.
27. Desmedt C, Di Leo A, Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, et al. Multi-factorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011;29:1578-86.
28. Harrell FE J, Califf R, Pryor D, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6. (Pubitemid 12155954)
29. Schnitt SJ. The transition fromductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res 2009;11:101.
30. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503. (Pubitemid 30262444)
31. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009;66:2219-30.
32. Contié S, Voorzanger-Rousselot N, Litvin J, Clézardin P, Garnero P. Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer 2011;128:352-60.
33. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011;223:307-17.
34. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008;13:394-406. (Pubitemid 351609443)
35. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005;65:6493-7. (Pubitemid 41060680)